Group 1 - The core viewpoint of the article highlights the significant stock performance of JunTai Holdings, with a recent increase of 465.22% over the past month and 116.67% year-to-date, outperforming the Hang Seng Index by 19.78% [1] - As of December 31, 2024, JunTai Holdings reported total revenue of 34.9969 million yuan, a year-on-year increase of 10.07%, and a net profit attributable to shareholders of -1.1418 million yuan, reflecting a year-on-year growth of 55.21% [1] - The company's gross profit margin stands at 36.89%, with a debt-to-asset ratio of 62.26% [1] Group 2 - JunTai Holdings operates primarily in the manufacturing and sales of medical equipment products, plastic molds, and data media products, having expanded its medical equipment business through the acquisition of the Titron Group in October 2011 [2] - The average price-to-earnings (P/E) ratio for the healthcare equipment and services industry is -2.68 times, with a median of 1.17 times, while JunTai Holdings has a P/E ratio of -204.03 times, ranking 56th in the industry [1] - Comparatively, other companies in the industry have P/E ratios such as Giant Medical Holdings at 0.28 times, Jingjiu Health at 0.38 times, Yihui Group at 1.96 times, Global Medical at 5.24 times, and Ruici Medical at 5.4 times [1]
隽泰控股(00630.HK)7月11日收盘上涨9.62%,成交32.15万港元